188 related articles for article (PubMed ID: 22884142)
21. Identification and functional characterization of a novel homozygous intronic variant in the fumarylacetoacetate hydrolase gene in a Chinese patient with tyrosinemia type 1.
Chen J; Sun J; Li X; Du M
BMC Med Genomics; 2022 Dec; 15(1):251. PubMed ID: 36463171
[TBL] [Abstract][Full Text] [Related]
22. A minor alternative transcript of the fumarylacetoacetate hydrolase gene produces a protein despite being likely subjected to nonsense-mediated mRNA decay.
Dreumont N; Maresca A; Boisclair-Lachance JF; Bergeron A; Tanguay RM
BMC Mol Biol; 2005 Jan; 6():1. PubMed ID: 15638932
[TBL] [Abstract][Full Text] [Related]
23. [Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I].
Vondrácková A; Tesarová M; Magner M; Docekalová D; Chrastina P; Procházkova D; Zeman J; Honzík T
Cas Lek Cesk; 2010; 149(9):411-6. PubMed ID: 21117323
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong.
Mak CM; Lam CW; Chim S; Siu TS; Ng KF; Tam S
Clin Biochem; 2013 Jan; 46(1-2):155-9. PubMed ID: 23000314
[TBL] [Abstract][Full Text] [Related]
25. The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1).
Chi H; Gan C; Jiang Y; Chen D; Qiu J; Yang Q; Chen Y; Wang M; Yang H; Jiang W; Li Q
Mol Genet Genomic Med; 2023 Jan; 11(1):e2090. PubMed ID: 36369907
[TBL] [Abstract][Full Text] [Related]
26. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
BMC Genet; 2001; 2():9. PubMed ID: 11476670
[TBL] [Abstract][Full Text] [Related]
27. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
28. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
[TBL] [Abstract][Full Text] [Related]
29. Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
Morrow G; Dreumont N; Bourrelle-Langlois M; Roy V; Tanguay RM
Mol Genet Metab; 2019 May; 127(1):58-63. PubMed ID: 30954369
[TBL] [Abstract][Full Text] [Related]
30. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I.
Elpeleg ON; Shaag A; Holme E; Zughayar G; Ronen S; Fisher D; Hurvitz H
Hum Mutat; 2002 Jan; 19(1):80-1. PubMed ID: 11754109
[TBL] [Abstract][Full Text] [Related]
31. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
[TBL] [Abstract][Full Text] [Related]
32. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
33. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
34. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
[TBL] [Abstract][Full Text] [Related]
35. Hereditary tyrosinaemia type I in Norway: incidence and three novel small deletions in the fumarylacetoacetase gene.
Bliksrud YT; Brodtkorb E; Backe PH; Woldseth B; Rootwelt H
Scand J Clin Lab Invest; 2012 Sep; 72(5):369-73. PubMed ID: 22554029
[TBL] [Abstract][Full Text] [Related]
36. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
37. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
[TBL] [Abstract][Full Text] [Related]
38. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
39. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery.
Held PK; Olivares EC; Aguilar CP; Finegold M; Calos MP; Grompe M
Mol Ther; 2005 Mar; 11(3):399-408. PubMed ID: 15727936
[TBL] [Abstract][Full Text] [Related]
40. Nonsense mediated decay of VWF mRNA subsequent to c.7674-7675insC mutation in type3 VWD patients.
Shahbazi S; Baniahmad F; Zakiani-Roudsari M; Raigani M; Mahdian R
Blood Cells Mol Dis; 2012 Jun; 49(1):48-52. PubMed ID: 22503077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
